title: Effects of a MAO-B inhibitor in the treatment of Alzheimer disease.
abstract: 119 patients were enrolled in a double-blind randomized parallel study versus placebo carried out to assess both the efficacy and tolerability of L-deprenyl (10 mg/day) for treatment of patients with organic mental disorders of the Alzheimer type (DAT). The treatments were given for 3 months, starting after a run-in period of 15 days to evaluate efficacy. A complete neuropsychological battery was administered monthly after the start of treatment whereas tolerability was assessed by checking, recording and classifying all the unfavorable experiences occurring. According to the results, L-deprenyl would seem to be a useful and reliable tool for the treatment of DAT patients in an attempt to improve their cognitive functions and reduce behavioral alterations, without frequent or severe side effects.
authors.affiliation: Third Clinic of Neurology, University of Milan, Italy.
authors.forename: A
authors.initials: A
authors.lastname: Mangoni
authors.forename: M P
authors.initials: MP
authors.lastname: Grassi
authors.forename: L
authors.initials: L
authors.lastname: Frattola
authors.forename: R
authors.initials: R
authors.lastname: Piolti
authors.forename: S
authors.initials: S
authors.lastname: Bassi
authors.forename: A
authors.initials: A
authors.lastname: Motta
authors.forename: A
authors.initials: A
authors.lastname: Marcone
authors.forename: S
authors.initials: S
authors.lastname: Smirne
mesh_terms: D000203:Activities of Daily Living; D000368:Aged; D000544:Alzheimer Disease / Q000188:drug therapy*; D004311:Double-Blind Method; D006801:Humans; D008297:Male; D008875:Middle Aged; D009483:Neuropsychological Tests; D011379:Prognosis; D012642:Selegiline / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D012642:Selegiline